Development and validation of LC-MS/MS method for simultaneous determination of sofosbuvir and daclatasvir in human Plasma: Application to pharmacokinetic study-Reference-Cited by-同舟云学术

Development and validation of LC-MS/MS method for simultaneous determination of sofosbuvir and daclatasvir in human Plasma: Application to pharmacokinetic study

Published:2018-01-29 Issue:6 Volume:32 Page:e4186
ISSN:0269-3879
Container-title:Biomedical Chromatography
language:en
Short-container-title:Biomedical Chromatography

Author:

Abdallah Ola M.¹²,Abdel-Megied Ahmed M.³^ORCID,Gouda Amira S.⁴

Affiliation:

1. Analytical Chemistry Department, Faculty of Pharmacy; Al-Azhar University (Girls); Cairo Egypt

2. Pharmaceutical Chemistry Department, Faculty of Pharmacy; Badr University in Cairo (BUC); Badr City Cairo Egypt

3. Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy and Pharmaceutical Manufacturing; Kafrelsheikh University; Kafrelsheikh City Egypt

4. Zi-diligence Research Center; Cairo Egypt

Publisher

Wiley

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,General Medicine,Biochemistry,Analytical Chemistry

Reference34 articles.

1. Development a validated highly sensitive LC-MS/MS method for simultaneous quantification of Ledipasvir, sofosbuvir and its major metabolite GS-331007 in human plasma: Application to a human pharmacokinetic study;Abdallah;Journal of Pharmaceutical and Biomedical Analysis,2017

2. A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma;Ariaudo;Journal of Pharmaceutical and Biomedical Analysis,2016

3. Electrochemical design of a new nanosensor based on cobalt nanoparticles, chitosan and MWCNT for the determination of daclatasvir: A hepatitis C antiviral drug;Azab;RSC Advances,2017

4. Validated stability-indicating HPLC-DAD method for determination of the recently approved hepatitis C antiviral agent daclatasvir;Baker;Annales Pharmaceutiques Françaises,2017

5. Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir;Belema;Journal of Medicinal Chemistry,2014

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Rapid, Sensitive, and High-throughput Method for the Simultaneous Determination of Antihypertensive Drug Combinations in Dog Plasma by UHPLC-MS/MS: The Assessment of Predicable Bioequivalence of In-vitro Dissolution Condition;Current Pharmaceutical Design;2024-09

2. A natural hydrophobic deep eutectic solvent-based microextraction method integrated with a spectrofluorimetric technique for the determination of daclatasvir as a direct-acting hepatitis C antiviral drug in plasma samples;Microchemical Journal;2023-09

3. A novel method to estimate the absorption rate constant for two-compartment model fitted drugs without intravenous pharmacokinetic data;Frontiers in Pharmacology;2023-05-04

4. Analytical approaches for determination of COVID-19 candidate drugs in human biological matrices;TrAC Trends in Analytical Chemistry;2023-03

5. Electrochemical sensor based on bio-inspired molecularly imprinted polymer for sofosbuvir detection;RSC Advances;2023